CEO Initiative Aims To Reduce Development Time For Alzheimer’s Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
A group of CEOs from Big Pharma, biotech and finance companies have joined forces with philanthropists and health care policy makers to call for a global action plan against Alzheimer's disease.
You may also be interested in...
Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.